SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 7.45% Passive Stake in Accelerate Diagnostics

Armistice Capital, LLC and Steven Boyd have disclosed a 7.45% passive ownership stake in Accelerate Diagnostics, Inc., holding 1,879,227 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd collectively own 1,879,227 shares of Accelerate Diagnostics, Inc. common stock.
• This represents a 7.45% ownership stake in the company.
• The shares are held for investment purposes in the ordinary course of business and not with the intent to change or influence control of the issuer.
• The percentage of ownership is calculated based on 25,210,392 shares outstanding as of March 17, 2025, as reported in Accelerate Diagnostics' Form 10-K filed on March 21, 2025.
• Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is deemed to beneficially own these securities.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by an institutional fund, which can be interpreted as a vote of confidence in the company's prospects, though it provides no operational or financial updates.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, have taken a substantial 7.45% stake in Accelerate Diagnostics, Inc., which can be interpreted as a vote of confidence in the company's prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor holding 7.45% of common stock, potentially influencing market perception and trading activity.

Key Dates

Keywords

Accelerate Diagnostics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, passive investment, common stock, institutional investor